Amosartan
1st fixed-dose combination drug introduced in Korea
Amosartan Q
Controls Hypertension and Dyslipidemia at single treatment
Amosartan Plus
Treatment to patient not adequately controlled on agent double combo FDCs
Amosartan XQ
Controls Hypertension and Dyslipidemia at single treatment
Rosuzet
Increased efficacy due to improved lipid level control
Gugutams
A novel treatment option for ED patients accompanied by BPH
Monterizine
40% of allergic rhinitis patients accompanied by asthma , 80% of asthma patients accompanied by allergic rhinitis
Hyalrheuma injection
CE certified by SGS as a class-3 medical device
Esomezol DR
Dual release concept of Esomeprazole which can prevent NAB(Nocturnal Acid Breakthrough) symptom
Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021
Apr 14, 2021
FDA Grants Fast Track Designation to Spectrum Pharmaceuticals’ Poziotinib
Apr 14, 2021
Hanmi collaborated with MSD has launched Rosuzet the First Overseas Market in Mexico
Mar 05, 2021
